An investigational endoscopic procedure has shown early promise in helping patients maintain weight loss after stopping tirzepatide.
Early results from the first randomised sham-controlled trial of duodenal mucosal resurfacing suggest the procedure could help address one of obesity medicine’s biggest challenges: preventing weight regain after GLP-1 therapy ends.
Patients who undergo an investigational endoscopic “gut reset” procedure after discontinuing tirzepatide may be significantly less likely to regain lost weight than those receiving a sham intervention, according to interim results from the REMAIN-1 trial presented at Digestive Disease Week (DDW) 2026.
The findings address a major limitation of GLP-1-based obesity therapies. Although these medicines produce substantial weight loss, many patients discontinue treatment because of cost, adverse effects, or reluctance to remain on lifelong therapy, with most regaining a significant proportion of lost weight within 18 months.
Researchers evaluated duodenal mucosal resurfacing (DMR), an investigational outpatient endoscopic procedure that uses controlled thermal energy to ablate the duodenal mucosa, stimulating regeneration of new tissue.
The approach is designed to restore normal gut signalling disrupted by obesity and high-fat, high-sugar diets, potentially helping to preserve the metabolic benefits achieved with GLP-1 therapy.
Lead investigator Dr Shelby Sullivan, director of the Endoscopic Bariatric and Metabolic Program at Dartmouth Health Weight Center in the US, said identifying an effective strategy to maintain weight loss after discontinuing GLP-1 therapy represented a major unmet clinical need.
“As effective as GLP-1 medications are, many people stop taking them because of cost, side effects or simply not wanting to take a drug long-term,” she said.
“But, if they stop these medications, weight regain occurs in the vast majority of patients, and the metabolic benefits are lost.
“Finding a treatment that allows patients to stop these medications without weight regain or loss of metabolic benefit is a huge unmet need. These findings indicate that this minimally invasive procedure may provide lasting weight-loss maintenance.”
The multicentre, double-blind, randomised, sham-controlled REMAIN-1 trial enrolled patients who had lost at least 15% of their total body weight while receiving tirzepatide before discontinuing the drug. Participants were then randomised to undergo either DMR or a sham procedure.
The interim analysis included the first 45 participants to complete six months of follow-up, with 29 undergoing DMR and 16 receiving the sham intervention.
Participants had lost approximately 18kg while taking tirzepatide. Six months after stopping treatment, patients in the sham group had regained around 40% more weight than those who underwent DMR.
Among patients receiving more extensive mucosal resurfacing, average weight regain was approximately 3.2kg, allowing them to maintain more than 80% of their original weight loss.
In contrast, participants in the sham group regained about twice that amount.
Related
Investigators also reported that the difference between treatment groups appeared to widen between one and six months after the procedure, suggesting the effect may become more pronounced over time rather than diminish.
“What’s particularly encouraging is that the benefit appears to increase over time rather than fade, and that it behaves like a drug in terms of dose response,” Dr Sullivan said.
“That gives us confidence that we’re targeting the right biology.”
No serious complications were reported in the interim cohort.
Dr Sullivan said recovery following the procedure was minimal, with most patients returning to normal activities within a day.
Because symptoms after the procedure were limited, participants were unable to distinguish whether they had received the active treatment or the sham intervention, supporting the integrity of the trial’s blinding.
The proposed mechanism targets the duodenum, where many hormones involved in glucose metabolism and appetite regulation originate. Investigators suggest chronic exposure to energy-dense diets causes structural changes within the duodenal mucosa that alter hormonal signalling and contribute to insulin resistance and obesity.
By removing the altered mucosal layer and allowing regeneration of healthier tissue, DMR aims to “reset” gut metabolism so that the body better maintains its lower post-weight-loss set point after GLP-1 withdrawal.
The technology remains investigational. The pivotal REMAIN-1 program has enrolled more than 300 participants and is fully randomised.
Top-line six-month results from the full pivotal cohort are expected later in 2026, with sponsor Fractyl Health planning a regulatory submission if outcomes are favourable.
If confirmed in the larger study, DMR could offer an alternative to indefinite pharmacotherapy for selected patients with obesity.
However, the current findings represent an interim analysis from fewer than 50 participants with only six months of follow-up, and longer-term durability and broader safety data will be needed before the procedure’s role in clinical practice can be established.
